|
1.
|
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. MedStar authors:
Year: 2023
Citation: - Breast Cancer Research & Treatment. 199(2):243-252, 2023 Jun.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
- Journal Article
- Randomized Controlled Trial
All authors: - Azar CA, Baez-Diaz L, Bandos H, Bear HD, Boileau JF, Brufsky AM, Geyer CE Jr Hassan S, Magrinat GC, Mamounas EP, Paik S, Rastogi P, Sarwar S, Shibata HR, Suga JM, Swain SM, Tang G, Wolmark N, Yothers G
|
|
2.
|
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. MedStar authors:
- Kurian, Shweta
- Mohebtash, Mahsa
- Ottaviano, Yvonne
- Rao, Suman
- Swain, Sandra M
Year: 2022
Citation: - Breast Cancer Research & Treatment. 196(3):571-581, 2022 Dec.
Institution: - MedStar Franklin Square Medical Center
Department:
- Associate Dean for Research Development
- Hematology/Oncology
- MedStar Health
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Randomized Controlled Trial
All authors: - Dilawari A, Graham D, Isaacs C, Kurian S, Lynce F, Mainor C, McNamara D, Mohebtash M, Ottaviano Y, Pohlmann PR, Rao S, Swain SM, Swanson N, Tan M, Warren R, Wu T
|